Comparative Pharmacology
Head-to-head clinical analysis: THIOLA versus TIOPRONIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIOLA versus TIOPRONIN.
THIOLA vs TIOPRONIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiola (tiopronin) acts as a reducing agent, breaking disulfide bonds in cystine stones and decreasing cystine excretion by forming a soluble disulfide complex with cystine, thereby reducing urinary cystine concentration.
Tiopronin is a thiol compound that reduces cystine excretion by forming a soluble disulfide complex with cystine, thereby preventing cystine stone formation in patients with cystinuria. It also has antioxidant and anti-inflammatory properties, possibly through metal chelation and free radical scavenging.
300 mg orally three times daily (total daily dose 900 mg) 1 hour before meals and at bedtime.
500-1000 mg orally three times daily for cystinuria; for rheumatoid arthritis: 250 mg orally four times daily, titrated up to 500 mg four times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in adults with normal renal function. In patients with renal impairment, half-life may be prolonged, requiring dose adjustment.
Terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function. May be prolonged in renal impairment.
Primarily renal: approximately 60-70% of an administered dose is excreted in urine as unchanged drug or as the disulfide dimer. Minor biliary/fecal excretion accounts for <10%.
Renal: ~80% as unchanged drug and metabolites, primarily via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<5%).
Category C
Category C
Cystine Depleting Agent
Cystine Depleting Agent